NC 2500

Drug Profile

NC 2500

Alternative Names: NC-2500

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nippon Chemiphar
  • Class
  • Mechanism of Action Xanthine dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Hyperuricaemia

Highest Development Phases

  • Phase I Hyperuricaemia

Most Recent Events

  • 30 Nov 2017 Nippon completes a phase I trial in Hyperuricaemia in Japan
  • 10 Jul 2013 NC 2500 is available for licensing as of 31 Mar 2013.
  • 31 Mar 2013 Phase-I clinical trials in Hyperuricaemia in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top